BEXIMCO PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.1 BDT | -0.43% |
|
-1.36% | -20.59% |
| Mar. 04 | Beximco names Iqbal Ahmed as managing director | AN |
| Jan. 30 | Beximco Pharmaceuticals to strengthen portfolio as interim profit up | AN |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 33,864 | 28,065 | 79,096 | 68,969 | 65,222 | 51,794 | - | - |
| Enterprise Value (EV) 1 | 33,864 | 37,934 | 86,052 | 80,148 | 65,222 | 57,787 | 52,677 | 47,306 |
| P/E ratio | 11.2 x | 7.98 x | 15.4 x | 13.5 x | 14.1 x | 9.44 x | 7.69 x | 6.11 x |
| Yield | 1.8% | 2.17% | 1.97% | 2.26% | - | 3.45% | 4.31% | 5.17% |
| Capitalization / Revenue | 1.48 x | 1.1 x | 2.68 x | 1.99 x | 1.66 x | 1.16 x | 1.03 x | 0.9 x |
| EV / Revenue | 1.48 x | 1.48 x | 2.92 x | 2.31 x | 1.66 x | 1.3 x | 1.04 x | 0.83 x |
| EV / EBITDA | 5.64 x | 5.64 x | 11.1 x | 9.38 x | - | 5.91 x | 4.7 x | 3.63 x |
| EV / FCF | -23.2 x | 11.5 x | 24.6 x | 34.9 x | - | 12.1 x | 8.52 x | 6.3 x |
| FCF Yield | -4.3% | 8.7% | 4.06% | 2.87% | - | 8.26% | 11.7% | 15.9% |
| Price to Book | 1.14 x | 0.86 x | 2.14 x | 1.7 x | - | 1.09 x | 1 x | 0.9 x |
| Nbr of stocks (in thousands) | 446,112 | 446,112 | 446,112 | 446,112 | 446,112 | 446,112 | - | - |
| Reference price 2 | 75.91 | 62.91 | 177.3 | 154.6 | 146.2 | 116.1 | 116.1 | 116.1 |
| Announcement Date | 11/11/19 | 11/11/20 | 11/2/21 | 11/8/22 | 11/1/23 | - | - | - |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Giugno | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 22,817 | 25,612 | 29,494 | 34,669 | 39,267 | 44,551 | 50,494 | 57,302 |
| EBITDA 1 | 6,009 | 6,723 | 7,765 | 8,543 | - | 9,785 | 11,203 | 13,018 |
| EBIT 1 | 5,066 | 5,609 | 6,651 | 6,901 | 7,216 | 7,905 | 8,962 | 10,251 |
| Operating Margin | 22.2% | 21.9% | 22.55% | 19.91% | 18.38% | 17.74% | 17.75% | 17.89% |
| Earnings before Tax (EBT) 1 | 3,946 | 4,653 | 6,378 | 6,687 | 6,069 | 6,914 | 8,125 | 9,691 |
| Net income 1 | 3,033 | 3,515 | 5,141 | 5,123 | 4,612 | 5,132 | 6,000 | 7,168 |
| Net margin | 13.29% | 13.72% | 17.43% | 14.78% | 11.74% | 11.52% | 11.88% | 12.51% |
| EPS 2 | 6.800 | 7.882 | 11.49 | 11.48 | 10.34 | 12.30 | 15.10 | 19.00 |
| Free Cash Flow 1 | -1,457 | 3,299 | 3,498 | 2,299 | - | 4,776 | 6,184 | 7,514 |
| FCF margin | -6.38% | 12.88% | 11.86% | 6.63% | - | 10.72% | 12.25% | 13.11% |
| FCF Conversion (EBITDA) | - | 49.07% | 45.04% | 26.91% | - | 48.81% | 55.2% | 57.72% |
| FCF Conversion (Net income) | - | 93.86% | 68.04% | 44.87% | - | 93.06% | 103.07% | 104.83% |
| Dividend per Share 2 | 1.364 | 1.364 | 3.500 | 3.500 | - | 4.000 | 5.000 | 6.000 |
| Announcement Date | 11/11/19 | 11/11/20 | 11/2/21 | 11/8/22 | 11/1/23 | - | - | - |
1BDT in Million2BDT
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 9,869 | 6,956 | 11,179 | - | 5,993 | 884 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 4,488 |
| Leverage (Debt/EBITDA) | - | 1.468 x | 0.8958 x | 1.309 x | - | 0.6125 x | 0.0789 x | - |
| Free Cash Flow 1 | -1,457 | 3,299 | 3,498 | 2,299 | - | 4,776 | 6,184 | 7,515 |
| ROE (net income / shareholders' equity) | 10.6% | 11.2% | 14.8% | 13.2% | - | 11.6% | 13% | 14.7% |
| ROA (Net income/ Total Assets) | 6.53% | 7.08% | 10% | - | - | 7.6% | 8.9% | 10.9% |
| Assets 1 | 46,476 | 49,642 | 51,182 | - | - | 67,526 | 67,416 | 65,766 |
| Book Value Per Share 2 | 66.30 | 72.80 | 83.00 | 91.00 | - | 106.0 | 116.0 | 129.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 2,244 | 2,526 | 2,915 | - | 2,090 | 1,000 | 1,000 |
| Capex / Sales | - | 8.76% | 8.56% | 8.41% | - | 4.69% | 1.98% | 1.75% |
| Announcement Date | 11/11/19 | 11/11/20 | 11/2/21 | 11/8/22 | 11/1/23 | - | - | - |
1BDT in Million2BDT
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
116.1
BDT
Average target price
153.5
BDT
Spread / Average Target
+32.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 472M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BXPHARMA Stock
- Financials Beximco Pharmaceuticals Limited
